Screening of Tumor Endothelial Cell Specific MarkerDoppelfor Prediction of Anti-Cancer Effect

Abstract

DoppelProtein is a tumor endothelial cell (TEC) specific marker which has a unique mechanism. It is known to interact with VEGFR 2 on the surface of the tumor endothelial cells specifically which inhibit the internalization of the VEGFR 2. This phenomenon induces uncontrolled angiogenesis in tumor site that leads to tumor growth. Herein, this study screens out theDoppelprotein by different tumor types which hypothesize thatDoppelprotein could be a possible biomarker and target site for further anti-cancer studies. In order to overcome the conventional anti-angiogenic drugs limitation, non-specificity and toxicity, using 'Doppel' protein will be an efficient and novel approach for anti-angiogenic drugs for anti-cancer effect. This study used immunohistochemistry, Western blot, and flow cytometry analysis to confirm the hypothesis. Indeed, the expression levels of this protein differ by the different types of tumor, and this characteristic can be distinguishable for further analysis. The protein level difference gives the possibility of using the 'Doppel' protein as a target site forDoppelantibody and biomarker for the effective therapeutics.